[go: up one dir, main page]

WO2023110062A1 - Dispositif d'inhalation de mousse - Google Patents

Dispositif d'inhalation de mousse Download PDF

Info

Publication number
WO2023110062A1
WO2023110062A1 PCT/EP2021/085671 EP2021085671W WO2023110062A1 WO 2023110062 A1 WO2023110062 A1 WO 2023110062A1 EP 2021085671 W EP2021085671 W EP 2021085671W WO 2023110062 A1 WO2023110062 A1 WO 2023110062A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
foam
accordance
liquid
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/085671
Other languages
English (en)
Inventor
Klaus Hagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Splash TM GmbH
Original Assignee
Splash TM GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Splash TM GmbH filed Critical Splash TM GmbH
Priority to PCT/EP2021/085671 priority Critical patent/WO2023110062A1/fr
Publication of WO2023110062A1 publication Critical patent/WO2023110062A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/30—Devices using two or more structurally separated inhalable precursors, e.g. using two liquid precursors in two cartridges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes

Definitions

  • the invention relates to a process for preparing a consumable serving for absorption through the human mouth in low-dose amounts by at least partial mixing of at least one liquid and at least one substance, whereby the liquid and/or the substance serve as an active ingredient carrier.
  • the invention relates to a consumable for absorption through the human mouth in small doses, prepared by at least partial mixing of at least one liquid and/or at least one substance in a device, preferably in an inhalation device.
  • the invention relates to an inhalation device for the preparation and delivery of low-dose amounts of a consumable by at least partial mixing of at least one liquid and at least one substance.
  • the invention relates to a capsule for insertion into an inhalation device for the preparation and delivery of low-dose amounts of a consumable by at least partial mixing of a liquid and a substance, held in at least two chambers of the capsule, wherein the liquid and/or the substance serve as an active ingredient carrier.
  • Inhalation devices or inhalers are mainly familiar from medicine. They are used to generate aerosols, which are then inhaled by patients as part of therapy. It is important that the active ingredients are specifically and precisely absorbed by the lungs, e.g. to remedy pulmonary or colds.
  • effervescent powder and water have always enjoyed great popularity, especially among children and young people.
  • Sufficiently known are e.g. sherbets as carbonated soft drinks.
  • powder usually available in bags is mixed in a glass, cup or even in the bag to a bubbling effervescent drink. Because the powder is supposed to react intensively with the water, it comes beyond the pure drinking pleasure to a fun factor associated with the production of the drink.
  • Such devices are known from the GB 2586301 .
  • the teaching of GB 2586301 discloses the chemical reaction of a substance that releases carbon dioxide gas to form the foam of the soft drink according to the invention and e.g. provides for the endothermic reaction between soda and citric acid.
  • CO 2 forms unstable, short-lived bubbles at the I iquid/gas interface. Bubbles burst immediately due to the high surface tension.
  • the present invention has the task of creating a process for the preparation of a suitable consumable, a consumable, an inhalation device for the preparation and delivery of low-dose amounts of such a consumable and a capsule for insertion into an inhalation device for the preparation and delivery of low-dose amounts of a consumable.
  • This purpose is achieved by a manufacturing process in accordance with claim 1 .
  • a capsule for insertion into an inhalation device for the preparation and delivery of low-dose amounts of a foam-like soft drink is given.
  • a liquid and a substance are each stored in a chamber of the capsule and then specifically destroyed via the activation to such an extent that a deliberate and intentional leak of the mixture occurs.
  • Such a consumable may be enjoyed in a low-dose quantity such as a shot.
  • This foam production then exits the capsule and enters the consumer's body through the inhaler.
  • this purpose may be achieved by an inhalation device in accordance with claim 8.
  • a liquid and/or a substance serve as an active ingredient carrier. They are each stored in a chamber in a capsule and then specifically destroyed via the activation mechanism at least to such an extent that it comes to a deliberate and intentional leakage of the mixture.
  • the active ingredient can be a "ready mixed” formula like an energy drink or an alcoholic composition (like any cocktail, wine or any pre-bottled alcohol) or it can be an “add on” raw material of those substances that are called “active ingredients” (like some caffeine powders or some drops of nicotine).
  • active ingredients like some caffeine powders or some drops of nicotine.
  • the percentage can vary from 50-100%, and in the case of an "add on” raw material it can vary from 1-10%.
  • an inhalation device for the production and delivery of low-dose amounts of a consumable by at least partial mixing of a liquid and at least one substance is possible.
  • the inhalation device comprises at least two chambers, which serve to receive a liquid or a substance.
  • mixing only occurs under the condition that the consumer activates a manufacturing process by destroying e.g. the partition wall between different chambers. This foam production "on site” then exits the capsule and enters the consumer's body through the inhaler.
  • the initial step of this process is the tablet solvation in contact with water forms hydrated ions with the duration like slow, taking several minutes.
  • the main reaction is about an instable hydrogen carbonate ion break down into water and gaseous CO 2 , very fast, ⁇ 1 ms.
  • the third step is the CO 2 release showing CO 2 bubbles are formed when saturation limit is reached. The duration for this third step is rather fast.
  • the capsule for insertion into an inhalation device, the capsule is part of a multi-chamber system whose function is triggered and/or controlled by a suitable activation mechanism.
  • Foam as such proves to be an excellent carrier for active ingredients of any kind, because these substances are activated during foam formation and are immediately available for use in connection with an inhalation device according to the invention. As soon as the foam enters the mouth, it is quickly absorbed directly into the bloodstream via the oral mucosa so that it can unfold its desired effect.
  • a preferred embodiment of the invention provides that the liquid comprises a foam emulsifier and/or a foam stabilizer.
  • One effect is that the surface tension is reduced by dispersing small amounts of emulsifiers or surfactants.
  • various foodsafe substances can be used as a foam emulsifier or foam stabilizer, which must be added to the formulation according to the invention to obtain a fine and stable foam.
  • the proportion of foam emulsifier and/or foam stabilizer in the liquid should be 10% to 30%, preferably about 20%.
  • the foam formation rate is mainly determined by the solvation speed of acid and carbonate mixtures. A powder dissolves much faster in comparison to a compressed tablet. Fine adjustment is achievable by pressing the tablet at different forces that result in increasing hardness at higher forces. Tablet solvation can range from a couple of seconds up to several minutes. Physical properties, mainly viscosity and density of liquid can impact foam formation speed as well. The lower liquid’s fluidity becomes the longer foam generation takes.
  • the development target is about longlife stable and white foam with homogenous bubbles are as distribution. The lifetime of bubbles is limited by a mechanical cracking, water evaporation, gravimetry and the gas type.
  • lecithin, mono- or diglyceride, xanhan, maltrodextine, aspuma, agar and/or SucroAir expediently serve as a foam emulsifier and/or as a foam stabilizer.
  • the use of further emulsifiers and stabilizers is conceivable.
  • Consumers take foam in portions of 0.1 to 0.3 gram from the device. This amount can be adjusted by the density of the mouth and filter plug and depends on users inhaling behaviour. That means how long someone presses the valve button and how intensely the user inhales. The relatively small amount provides the surprisingly intense taste and smell sensation.
  • the starting point for a foam in the sense of the invention is two or more substances that are held separately in such a capsule until the wall between the two or more chambers is broken, which can trigger the process of merging these substances and their distribution for consumption.
  • foam formation is accompanied by an activation of the active ingredient.
  • the process according to the invention teaches that the foam is only produced when the consumer activates the foaming process, for which the partition wall between the individual chambers has to be broken through.
  • the liquid filling volumes range from 3.5 to 4mL, all kinds of water-based juices and beverages with dispersed emulsifiers are suitable.
  • the standard recipe is 40/60 mixture of citric acid and sodium hydrogen carbonate.
  • the maximal foam volume can be estimated from the reaction equation of the effervescent tablet.
  • One tab delivers 68 mL.
  • an over pressure inside the bubbles of about 5% and a loss of 10% at the interface between foam and ambient air a total foam volume of about 55 mL could be achievable.
  • active ingredients There are almost no limits as far as the selection of active ingredients is concerned. It is to be regarded as advantageous if nicotine, caffeine, alcohol, a vitamin mixture, light pharmaceutical substances and/or sleeping pills serve as active ingredients, i.e. stimulating or calming substances as well.
  • the active ingredient can be a "ready-made" formula, as is the case for an energy drink or an alcoholic composition, as is ultimately the case with any alcoholic beverage.
  • the proportion of active ingredient is between 50% and 100%, with an additive this can preferably vary between 1 % and 10%.
  • an effervescent serves as an active ingredient carrier, while the liquid with foam emulsifiers and/or foam stabilizers serves as a flavour enhancer, that the emulsifiers and stabilizers thus take over the role of such a flavour enhancer.
  • the activation mechanism comprises a needle or tube used to break through the wall between the chambers reflects the first function of such a mechanism, namely the destruction of a chamber wall by means of the activation mechanism as a function of the pressure applied manually to the capsule.
  • a further advantageous embodiment of the invention provides that the activation mechanism comprises a needle or a tube which serves as an agent for the exit of the generated foam from the capsule.
  • a needle or tube serves to break through the wall between the chambers and to expel the generated foam from the capsule.
  • the mechanical instrument in the form of a needle or tube thus ideally works in a double function.
  • This foam production "on site” then exits the capsule and enters the consumer's body through an inhaler in which the capsule is inserted or by being an integral part of an inhaler.
  • an inhaler in which the capsule is inserted or by being an integral part of an inhaler.
  • This is to be understood as a needle or tube used to break through the wall between the chambers and to expel the generated foam from the capsule.
  • the formula can be prepared in various ways by mixing or supporting measures before storage in one of the chambers of the capsule.
  • Simple stirring is intended or above all professional, even grinding of the substances, if necessary paired with a stirring of the substances with rotors that work with very high torques.
  • the inhaler is designed with a stirring or grinding device.
  • the invention is characterized in particular in that a capsule for insertion into an inhalation device for the preparation and delivery of low-dose amounts of a foam-like soft drink is given.
  • a liquid and a substance are each stored in a chamber of the capsule and then specifically destroyed via the activation mechanism at least to such an extent that a deliberate and intentional leak of the mixture occurs.
  • a special role is played by the liquid and the substance, which together or alone can serve as an active ingredient carrier, supported by a foam emulsifier and/or a foam stabilizer.
  • the foam formation leads to the activation of the active ingredient. That is, the foam is only produced when the consumer activates the foaming process by destroying the partition between the different chambers. This foam production "on site” then exits the capsule and enters the consumer's body through the inhaler.
  • soda/citric acid mixes are preferred because of their neutral taste and excellent foam formation potential. Particle size and shape of acid and carbonate must fit for a proper compressibility in the tablet pressing process on a homogenous distribution.
  • the figure shows a capsule 1 set in a inhalation device 14 which has a flexible mixing chamber 2, an expansion chamber 10 and a seal/connection 5 as well as an outlet 8.
  • a holder 12 for the capsule 1 There is a holder 12 for the capsule 1 .
  • the mixing chamber 12 is designed to be flexible and is used to hold a liquid in the case of the chamber 3 and to hold a substance in the case of the chamber 4.
  • An activation mechanism is denoted by 13, which is used to destroy the chamber 3 for the purpose of mixing or expansion.
  • the conduit 6 extends between an inlet 7and an outlet/mouthpiece 8 There are two parts 9 and 11 of the housing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé pour la préparation d'un produit consommable à ingérer par l'intermédiaire de la bouche humaine en de petites doses comprend le mélange au moins partiel d'au moins un liquide et d'au moins une substance, le liquide et/ou la substance servant de support de principe actif.
PCT/EP2021/085671 2021-12-14 2021-12-14 Dispositif d'inhalation de mousse Ceased WO2023110062A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/085671 WO2023110062A1 (fr) 2021-12-14 2021-12-14 Dispositif d'inhalation de mousse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/085671 WO2023110062A1 (fr) 2021-12-14 2021-12-14 Dispositif d'inhalation de mousse

Publications (1)

Publication Number Publication Date
WO2023110062A1 true WO2023110062A1 (fr) 2023-06-22

Family

ID=79283060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/085671 Ceased WO2023110062A1 (fr) 2021-12-14 2021-12-14 Dispositif d'inhalation de mousse

Country Status (1)

Country Link
WO (1) WO2023110062A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2586301A (en) 2020-04-07 2021-02-17 Consumernext Labs Gmbh Stable-Foam inhalation Device and Cartridge
GB2593789A (en) * 2020-04-07 2021-10-06 Splash Tm Gmbh Stable-foam inhalation device and cartridge

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2586301A (en) 2020-04-07 2021-02-17 Consumernext Labs Gmbh Stable-Foam inhalation Device and Cartridge
GB2593789A (en) * 2020-04-07 2021-10-06 Splash Tm Gmbh Stable-foam inhalation device and cartridge
WO2021204408A1 (fr) * 2020-04-07 2021-10-14 Splash Tm Gmbh Dispositif d'inhalation de mousse stable et cartouche

Similar Documents

Publication Publication Date Title
US3729553A (en) Packaged effervescent composition
AU2008269573B2 (en) An inhalable composition comprising nicotine
ES2280343T3 (es) Composiciones farmaceuticas que contienen cannabis.
US5456677A (en) Method for oral spray administration of caffeine
WO1999048469A1 (fr) Composition conçue pour degager un arome
JP6923776B1 (ja) 安定泡吸入器具およびカートリッジ
EP2262534A1 (fr) Composition solide agréable au goût comprenant un antiacide et un stimulant salivaire
WO2023110062A1 (fr) Dispositif d'inhalation de mousse
WO2018216019A1 (fr) Appareil permettant de distribuer un aérosol liquide à des surfaces de cavité buccale
US3947566A (en) Effervescent medicaments
JP7712987B2 (ja) 泡吐出容器入り液体口腔用組成物
US20090196832A1 (en) Novel edible aqueous aerosol foam
JP7382766B2 (ja) 発泡性固体浴用剤
KR101511572B1 (ko) 실리콘 흡착제를 이용하여 제조한 홍삼 발포정
JPS62502194A (ja) エ−ロゾル発泡体
AU2010317559B2 (en) Hydrosol based flavor delivery device
EP1064029A1 (fr) Procede de degagement d'un arome
US20230390508A1 (en) Nitric oxide nasal delivery apparatus and methods
US20230022521A1 (en) Nitric oxide nasal delivery apparatus and methods
TWI740832B (zh) 泡噴出容器裝之液體口腔用組合物
MXPA00009182A (en) Method for aroma delivery
JP2011236164A (ja) 粉末状入浴剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21839421

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21839421

Country of ref document: EP

Kind code of ref document: A1